OncoMatch/Clinical Trials/NCT07078591
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Is NCT07078591 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for acute myeloid leukemia.
Treatment: GPBMC infusion · Venetoclax · Azacitidine (AZA) · Daunorubicin · Idarubicin（IDA） · Cytarabine (Ara-C) — The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Prior therapy
Cannot have received: anti-acute leukemia treatment
Exception: prior hydroxyurea and/or leukapheresis are permitted
Lab requirements
Kidney function
serum creatinine <= 2 × ULN or CrCl >= 40 mL/min
Liver function
ALT and AST <= 3 × ULN, total bilirubin <= 1.5 × ULN
Cardiac function
LVEF > 50% by echocardiogram; no clinically significant cardiovascular disease (e.g., uncontrolled/highly symptomatic arrhythmias, CHF, MI within 6 months, NYHA class 3 or 4)
Adequate hepatic function including ALT and AST <= 3 × ULN, and total bilirubin <= 1.5 × ULN. Adequate renal function including serum creatinine <= 2 × ULN or CrCl >= 40mL/min. LVEF measured by echocardiogram is within the normal range (LVEF > 50%). Cardiovascular disease with clinical significance, such as uncontrolled or highly symptomatic cardiac arrhythmias, congestive heart failure, or myocardial infarction within 6 months prior to screening, or NYHA function class 3 (moderate) or class 4 (severe) heart disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07078591 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages